Catherine Hunt

Catherine Hunt serves as a procurement specialist responsible for managing acquisitions within the pharmaceutical manufacturing sector, ensuring alignment with federal regulatory and supply chain integrity standards. Her role centers on executing full lifecycle contract actions—from market research and solicitation development to award and performance oversight—primarily for finished pharmaceutical preparations. She plays a critical function in supporting mission-critical drug supply continuity, working closely with technical evaluators and compliance teams to ensure procurements meet stringent FDA and GMP requirements. Her acquisitions typically involve complex, high-integrity manufacturing contracts requiring rigorous quality assurance protocols and validated production environments. While no specific contractor relationships are currently identifiable in the data, Catherine consistently engages with a narrow but highly specialized pool of manufacturers certified under cGMP standards, including both large-scale pharmaceutical producers and niche contract development and manufacturing organizations (CDMOs). Her procurement approach emphasizes technical capability, regulatory compliance, and supply chain resilience over volume-based vendor selection, fostering long-term partnerships grounded in quality and consistency rather than price competitiveness alone. Catherine’s procurement portfolio reflects a singular focus on open competition, with 100% of her acquisitions issued under the “No Set-Aside” category. This indicates a deliberate strategy to prioritize technical excellence and regulatory compliance over socioeconomic preferences, aligning with the unique constraints of pharmaceutical manufacturing where only a limited number of qualified facilities meet federal standards. While small business participation is not formally targeted, her approach does not preclude qualified small entities that demonstrate full compliance with cGMP and FDA submission requirements. Her primary procurement focus is exclusively on NAICS 325412—Pharmaceutical Preparation Manufacturing—encompassing sterile injectables, oral solids, and other finished dosage forms. She specializes in procuring products requiring cold chain logistics, batch traceability, and controlled release technologies, demonstrating deep domain expertise in pharmaceutical quality systems, validation protocols, and Good Manufacturing Practices. Her work directly supports public health infrastructure through reliable access to essential medicines.